by Steven Grossman | Oct 6, 2025 | Uncategorized
This week’s questions:State public health officials are having to make difficult decisions about whether to follow CDC guidance on vaccines and other topics. Could there be a similar erosion of trust by states regarding FDA guidance?Anti-vaccine policies poll poorly...
by Steven Grossman | Sep 29, 2025 | Uncategorized
———This week’s questions:Is there something that received less attention but particularly concerns you? (Yes, termination of the Household Food Security survey)Will there be a government shutdown? What are the likely impacts for FDA if there is...
by Steven Grossman | Sep 15, 2025 | Uncategorized
This week’s questions:Is Secretary Kennedy at risk of losing his job?What is Kenvue? Doesn’t J&J make Tylenol?How realistic is it to dramatically shorten product review cycles? ———Q: Is Secretary Kennedy at risk of losing his job? A: Many...
by Steven Grossman | Sep 7, 2025 | Uncategorized
This week’s questions:What’s at stake when a CDC director won’t sign off on the Administration’s vaccine policies, is fired, and several senior center leaders resign? What happens next at CDC?What are the possible impacts of the CDC situation on FDA and...
by Steven Grossman | Sep 2, 2025 | Uncategorized
———This week’s questions:Did your column on MAHA intend to deliver a specific message to journalists and lead advocacy groups? What is the most critical FDA issue in September? What are some FDA issues that are simmering and will eventually surface?...
by Steven Grossman | Aug 25, 2025 | Uncategorized
———This week’s questions:Why has CDRH seemed uniquely untouched by this year’s upheaval at the FDA? How does the WSJ editorial on drug approvals (here) relate to your late July article (here) calling for a National Agenda for Advancing Therapies for...
